Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study

Pain

Volumn 152, Issue 9, 2011, Pages 1988-1996

  Ernberg, Malin ^a   Hedenberg Magnusson, Britt ^a,b   List, Thomas ^c   Svensson, Peter ^d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Eastman Dental Institute Stockholm   (Sweden)

^c MALMÖ UNIVERSITY   (Sweden)

^d AARHUS UNIVERSITY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Botulinum toxin; Masseter muscle; Pain; Randomized controlled study; Temporomandibular disorders

Indexed keywords

BOTULINUM TOXIN A; CITALOPRAM; CODEINE; GABAPENTIN; MIRTAZAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALICYLIC ACID; TRAMADOL; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; JAW PAIN; MALE; MASSETER MUSCLE; MENTAL PERFORMANCE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYOFASCIAL PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; BOTULINUM TOXINS, TYPE A; CHRONIC PAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOFASCIAL PAIN SYNDROMES; TEMPOROMANDIBULAR JOINT DISORDERS; TREATMENT OUTCOME;

EID: 80051784403     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2011.03.036     Document Type: Article

References (63)

1. K.R. Aoki Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A Neurotoxicology 26 2005 785 793 (Pubitemid 41427518)
2. W. Blersch, W.J. Schulte-Mattler, S. Przywara, A. May, H. Bigalke, and K. Wohlfarth Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study J Neurol Sci 205 2002 59 63 (Pubitemid 36158994)
3. H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment Eur J Pain 10 2006 287 333
4. M.F. Brin, S. Fahn, C. Moskowitz, A. Friedman, H.M. Shale, P.E. Greene, A. Blitzer, T. List, D. Lange, and R.E. Lovelace Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm Mov Disord 2 1987 237 254
5. T.T. Dao, and L. LeResche Gender differences in pain J Orofac Pain 14 2000 169 184
6. A. de Paiva, F.A. Meunier, J. Molgo, K.R. Aoki, and J.O. Dolly Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals Proc Natl Acad Sci USA 96 1999 3200 3205 (Pubitemid 29148868)
7. D.W. Dodick, C.C. Turkel, R.E. DeGryse, S.K. Aurora, S.D. Silberstein, R.B. Lipton, H.C. Diener, M.F. Brin PREEMPT Chronic Migraine Study Group Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program Headache 50 2010 921 936
8. D. Dressler Botulinum toxin therapy failure: causes, evaluation procedures and management strategies Eur J Neurol 4 1997 67 70
9. D. Dressler, and F. Adib Saberi Botulinum toxin: mechanisms of action Eur Neurol 53 2005 3 9 (Pubitemid 40522824)
10. R.H. Dworkin, D.C. Turk, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, N.P. Katz, R.D. Kerns, G. Stucki, R.R. Allen, N. Bellamy, D.B. Carr, J. Chandler, P. Cowan, R. Dionne, B.S. Galer, S. Hertz, A.R. Jadad, L.D. Kramer, D.C. Manning, S. Martin, C.G. McCormick, M.P. McDermott, P. McGrath, S. Quessy, B.A. Rappaport, W. Robbins, J.P. Robinson, M. Rothman, M.A. Royal, L. Simon, J.W. Stauffer, W. Stein, J. Tollett, J. Wernicke, and J. Witter IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations Pain 113 2005 9 19 (Pubitemid 40038441)
11. R.H. Dworkin, D.C. Turk, S. Peirce-Sandner, R. Baron, N. Bellamy, L.B. Burke, A. Chappell, K. Chartier, C.S. Cleeland, A. Costello, P. Cowan, R. Dimitrova, S. Ellenberg, J.T. Farrar, J.A. French, I. Gilron, S. Hertz, A.R. Jadad, G.W. Jay, J. Kalliomaki, N.P. Katz, R.D. Kerns, D.C. Manning, M.P. McDermott, P.J. McGrath, A. Narayana, L. Porter, S. Quessy, B.A. Rappaport, C. Rauschkolb, B.B. Reeve, T. Rhodes, C. Sampaio, D.M. Simpson, J.W. Stauffer, G. Stucki, J. Tobias, R.E. White, and J. Witter Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations Pain 149 2010 177 193
12. S.F. Dworkin, and L. LeResche Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique J Craniomandib Disord 6 1992 301 355
13. S.F. Dworkin, J. Sherman, L. Mancl, R. Ohrbach, L. LeResche, and E. Truelove Reliability, validity, and clinical utility of the research diagnostic criteria for Temporomandibular Disorders Axis II Scales: depression, non-specific physical symptoms, and graded chronic pain J Orofac Pain 16 2002 207 220
14. J.T. Farrar, R.K. Portenoy, J.A. Berlin, J.L. Kinman, and B.L. Strom Defining the clinically important difference in pain outcome measures Pain 88 2000 287 294
15. J.T. Farrar, J.P. Young Jr., L. LaMoreaux, J.L. Werth, and R.M. Poole Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain 94 2001 149 158 (Pubitemid 33016608)
16. B. Freund, and M. Schwartz The use of botulinum toxin for the treatment of temporomandibular disorder Oral Health 88 1998 32 37
17. P. Gazerani, K. Wang, B.E. Cairns, P. Svensson, and L. Arendt-Nielsen Effects of subcutaneous administration of glutamate on pain, sensitization and vasomotor responses in healthy men and women Pain 124 2006 338 348 (Pubitemid 44397257)
18. M.L. Grossi, M.B. Goldberg, D. Locker, and H.C. Tenenbaum Reduced neuropsychologic measures as predictors of treatment outcome in patients with temporomandibular disorders J Orofac Pain 15 2001 329 339 (Pubitemid 33646062)
19. L. Guarda-Nardini, D. Manfredini, M. Salamone, L. Salmaso, S. Tonello, and G. Ferronato Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study Cranio 26 2008 126 135
20. K.Y. Ho, and K.H. Tan Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review Eur J Pain 11 2007 519 527
21. G.J. Huang, L. LeResche, C.W. Critchlow, M.D. Martin, and M.T. Drangsholt Risk factors for diagnostic subgroups of painful temporomandibular disorders (TMD) J Dent Res 81 2002 284 288 (Pubitemid 41709809)
22. M.N. Janal, K.G. Raphael, S. Nayak, and J. Klausner Prevalence of myofascial temporomandibular disorder in US community women J Oral Rehabil 35 2008 801 809
23. M.T. John, S.F. Dworkin, and L.A. Mancl Reliability of clinical temporomandibular disorder diagnoses Pain 118 2005 61 69 (Pubitemid 41566586)
24. E. Kalso, and R.A. Moore Five easy pieces on evidence-based medicine (2) Eur J Pain 4 2000 321 324
25. C. Kurtoglu, O.H. Gur, M. Kurkcu, Y. Sertdemir, F. Guler-Uysal, and H. Uysal Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement J Oral Maxillofac Surg 66 2008 1644 1651 (Pubitemid 351970162)
26. S.J. Lee, W.D. McCall Jr., Y.K. Kim, S.C. Chung, and J.W. Chung Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial Am J Phys Med Rehabil 89 2010 16 23
27. T. List, and S. Axelsson Management of TMD: evidence from systematic reviews and meta-analyses J Oral Rehabil 37 2010 430 451
28. T.V. Macfarlane, A.S. Blinkhorn, R.M. Davies, J. Kincey, and H.V. Worthington Oro-facial pain in the community: prevalence and associated impact Community Dent Oral Epidemiol 30 2002 52 60
29. T.V. Macfarlane, R.J.M. Gray, J. Kincey, and H.V. Worthington Factors associated with the temporomandibular disorder, pain dysfunction syndrome (PDS): Manchester case-control study Oral Dis 7 2001 321 330 (Pubitemid 34072448)
30. Manfredini D, Ahlberg J, Winocur E, Guarda-Nardini L, Lobbezoo F. Correlation of RDC/TMD axis I diagnoses and axis II pain-related disability. A multicenter study. Clin Oral Investig 2010. doi:10.1007/s00784-010-0444-4.
31. D. Manfredini, M. Marini, C. Pavan, L. Pavan, and L. Guarda-Nardini Psychosocial profiles of painful TMD patients J Oral Rehabil 36 2009 193 198
32. D. Manfredini, E. Winocur, J. Ahlberg, L. Guarda-Nardini, and F. Lobbezoo Psychosocial impairment in temporomandibular disorders patients. RDC/TMD axis II findings from a multicentre study J Dent 38 2010 765 772
33. L. Mason, R.A. Moore, J.E. Edwards, S. Derry, and H.J. McQuay Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis BMC Musculoskelet Disord 5 2004 28
34. F.A. Meunier, G. Lisk, D. Sesardic, and J.O. Dolly Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation Mol Cell Neurosci 22 2003 454 466 (Pubitemid 36513569)
35. M. Naumann, Y. So, C.E. Argoff, M.K. Childers, D.D. Dykstra, G.S. Gronseth, B. Jabbari, H.C. Kaufmann, B. Schurch, S.D. Silberstein, and D.M. Simpson Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 2008 1707 1714 (Pubitemid 351644139)
36. D.R. Nixdorf, G. Heo, and P.W. Major Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain Pain 99 2002 465 473 (Pubitemid 35284278)
37. R. Ohrbach, J.A. Turner, J.J. Sherman, L.A. Mancl, E.L. Truelove, E.L. Schiffman, and S.F. Dworkin The research diagnostic criteria for temporomandibular disorders IV: evaluation of psychometric properties of the Axis II measures J Orofac Pain 24 2010 48 62
38. Peloso P, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie S, Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev 2007;(3):CD000319.
39. C.D. Petersen, A. Giraldi, L. Lundvall, and E. Kristensen Botulinum toxin type A - a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study J Sex Med 6 2009 2523 2537
40. D.D. Price, P.A. McGrath, A. Rafii, and B. Buckingham The validation of visual analogue scales as ratio scale measures for chronic and experimental pain Pain 17 1983 45 56 (Pubitemid 13004473)
41. J. Purkiss, M. Welch, S. Doward, and K. Foster Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms Biochem Pharmacol 59 2000 1403 1406 (Pubitemid 30177357)
42. E. Qerama, A. Fuglsang-Frederiksen, and T.S. Jensen The role of botulinum toxin in management of pain: an evidence-based review Curr Opin Anaesthesiol 23 2010 602 610
43. E. Qerama, A. Fuglsang-Frederiksen, H. Kasch, F.W. Bach, and T.S. Jensen A double-blind, controlled study of botulinum toxin A in chronic myofascial pain Neurology 67 2006 241 245 (Pubitemid 44305406)
44. D.R. Reissmann, M.T. John, R.W. Wassell, and A. Hinz Psychosocial profiles of diagnostic subgroups of temporomandibular disorder patients Eur J Oral Sci 116 2008 237 244
45. E.L. Schiffman, E.L. Truelove, R. Ohrbach, G.C. Anderson, M.T. John, T. List, and J.O. Look The research diagnostic criteria for temporomandibular disorders I: overview and methodology for assessment of validity J Orofac Pain 24 2010 7 24
46. W.J. Schulte-Mattler, P. Krack BoNTTH Study Group Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study Pain 109 2004 110 114 (Pubitemid 38479776)
47. W.J. Schulte-Mattler, and E. Leinisch Evidence based medicine on the use of botulinum toxin for headache disorders J Neural Transm 115 2008 647 651
48. L.C. Sellin, and S. Thesleff Pre- and post-synaptic actions of botulinum toxin at the rat neuromuscular junction J Physiol 317 1981 487 495 (Pubitemid 12205888)
49. B.J. Sessle Neural mechanisms and pathways in craniofacial pain Can J Neurol Sci 26 1999 S7 S11
50. E. Svensson Construction of a single global scale for multi-item assessments of the same variable Stat Med 20 2001 3831 3846
51. E.K. Tan, and J. Jankovic Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up Neurology 53 1999 2102 2107
52. E.K. Tan, and J. Jankovic Treating severe bruxism with botulinum toxin J Am Dent Assoc 131 2000 211 216
53. L.J. Taylor, and K. Herr Pain intensity assessment: a comparison of selected pain intensity scales for use in cognitively intact and cognitively impaired African American older adults Pain Manag Nurs 4 2003 87 95 (Pubitemid 36896575)
54. E.A. Tough, A.R. White, T.M. Cummings, S.H. Richards, and J.L. Campbell Acupuncture and dry needling in the management of myofascial trigger point pain: a systematic review and meta-analysis of randomised controlled trials Eur J Pain 13 2009 3 10
55. D.C. Turk, R.H. Dworkin, D. Revicki, G. Harding, L.B. Burke, D. Cella, C.S. Cleeland, P. Cowan, J.T. Farrar, S. Hertz, M.B. Max, and B.A. Rappaport Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain Pain 137 2008 276 285 (Pubitemid 351853291)
56. K. Wahlund, T. List, and S.F. Dworkin Temporomandibular disorders in children and adolescents: reliability of a questionnaire, clinical examination, and diagnosis J Orofac Pain 12 1998 42 51 (Pubitemid 128533759)
57. A.M. Velly, M. Gornitsky, and P. Philippe Contributing factors to chronic myofascial pain: a case-control study Pain 104 2003 491 499 (Pubitemid 37289048)
58. B. Voller, T. Sycha, B. Gustorff, L. Schmetterer, S. Lehr, H.G. Eichler, E. Auff, and P. Schnider A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A Neurology 61 2003 940 944 (Pubitemid 37248649)
59. J.J. von Lindern Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction Acta Neurol Belg 101 2001 39 41 (Pubitemid 32416743)
60. C.W. Whitney, and M. Von Korff Regression to the mean in treated versus untreated chronic pain Pain 50 1992 281 285
61. A.U. Yap, E.K. Chua, and J.K. Hoe TMD, pain-related disability and psychological status of TMD patients J Oral Rehabil 29 2002 374 380 (Pubitemid 41705140)
62. A.U. Yap, E.K. Chua, K.B. Tan, and Y.H. Chan Relationships between depression/somatization and self-reports of pain and disability J Orofac Pain 18 2004 220 225 (Pubitemid 39178319)
63. T. Zhang, A. Adatia, W. Zarin, M. Moitri, A. Vijenthira, R. Chu, L. Thabane, and W. Kean The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis Inflammopharmacology 19 2011 21 34